Tag: Pharmacoeconomics

In 2022, the global market for erythropoiesis-stimulating agents (ESAs) like PROCRIT was valued at approximately $4.8 billion, a testament to the high demand and equally high cost of these vital medications. This article explores the multifaceted reasons why is PROCRIT so expensive, examining the key drivers that contribute to its premium price tag.

According to Novartis, the manufacturer of Leqvio, the wholesale acquisition cost for uninsured patients is over $3,500 per dose, creating significant sticker shock for many. This high price tag leaves many patients and healthcare providers asking: why is Leqvio so expensive? The answer lies in a complex interplay of research costs, novel technology, patent protection, and market dynamics.

Priced at $4.25 million for a single infusion, Kyowa Kirin's Lenmeldy is currently the most expensive drug substance in the world. This one-time gene therapy is a groundbreaking treatment for the ultra-rare genetic disorder metachromatic leukodystrophy (MLD), highlighting the high costs associated with advanced therapeutic innovation.

Over 60% of the drugs on the World Health Organization's essential medicines list are classified as 'me-too' drugs, highlighting their widespread prevalence in healthcare. The question of whether these follow-on medications are justified, however, continues to be a contentious topic in the fields of pharmacology and pharmaceutical ethics.

As of 2025, the most expensive medication in the U.S. is Lenmeldy, a gene therapy priced at $4.25 million per dose [1.2.7]. This article answers **what is the most expensive medication in the US?** and explores the groundbreaking science and complex economics behind these costly treatments.

The estimated cost for treatment with enfortumab vedotin (Padcev) is approximately $17,718 per 28-day cycle [1.2.2]. This article explores the question, 'How much does enfortumab vedotin cost in the US?', by examining pricing, influencing factors, and financial support systems.

While generic phentermine has been available for a low price for decades, the cost of brand-name Qsymia has historically been significantly higher. Understanding **why is Qsymia more expensive than phentermine?** requires examining the core differences in their composition, FDA-approved usage, and market positioning.

Treating Cushing's disease often involves specialized medications, and the cost can be a significant concern for patients. Understanding **how much Isturisa costs** is crucial for those considering or currently undergoing treatment with this specific drug (osilodrostat). This article delves into the various facets of its pricing.

According to several pharmacoeconomic studies, the total treatment cost for certain infections with linezolid has been shown to be lower than with vancomycin, despite linezolid's significantly higher per-dose price. The question, 'Is linezolid more expensive than vancomycin?', therefore, requires a comprehensive look beyond just the initial drug cost to fully understand the financial implications for the healthcare system.

As of September 2025, Eli Lilly has not officially announced a price for its investigational oral weight loss and diabetes medication, orforglipron. With the average list price of current injectable GLP-1 drugs like Wegovy hovering around $1,300 per month, many anticipate orforglipron will be positioned to compete in the highly watched and expensive market for anti-obesity and diabetes treatments.